Christopher Morrison
Eluding simple characterization can present problems for aspiring drug companies: among investors, potential partners, and even management. Then again, it...
Archemix Reduces Aperture to Pursue Orphan Diseases
Archemix has consolidated IP in the aptamer space and enjoyed success in partnering its technology. But public markets have frozen the company out and it is now focusing on orphan hematologic diseases. The move should help the company conserve cash while creating earlier out-licensing opportunities as Archemix transitions into later-stage development.